AbinoNutra Introduces Dual-Therapy Approach for Cellular Longevity: NR and FDA-GRAS L-Ergothioneine Combination

WEST NEW YORK, NEW JERSEY / ACCESS Newswire / June 23, 2025 / Key Takeaways

• Telomere Economy - Repeated oxidative hits erode telomeres; lowering ROS may slow that decline.

• Dual-Axis Strategy - Pairing nicotinamide riboside (NR) with FDA-GRAS L-ergothioneine (EGT) may help deliver both NAD⁺ resupply and telomere shielding.

• Dose Logic - Ten milligrams per day EGT saturates the OCTN-1 transporter and is clinically tolerated.

• Early Signal - An AbinoPharm open-label pilot reported a 34 % median drop in urinary 8-OHdG after eight weeks of the NR + EGT liposomal blend.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

1 | Oxidative Stress Shrinks Telomeres Faster Than Chronological Time

Telomeres lose ~50-100 bp per cell division, but reactive oxygen species (ROS) can accelerate that loss five- to ten-fold (Samuel 2022). In human fibroblasts exposed to 200 µM H₂O₂, telomere attrition reached 400 bp per passage-a pace linked to premature replicative senescence.

L‑ergothioneine (EGT) is a rare sulfur amino‑acid taken up by OCTN‑1 transporters and preferentially retained in mitochondria & nuclei. Samuel et al. showed that 1-5 µM EGT preserved median telomere length and halved the proportion of critically short telomeres after eight weeks of oxidative culture stress.

2 | NAD⁺ Declines Create a Second Bottleneck-Energy for DNA Repair

Whole-blood NAD⁺ drops ~50 % between ages 40 and 60 (Conze 2019). Supplementing 500 mg NR daily raised NAD⁺ 51 % in 14 days and restored PARP- and SIRT-dependent repair pathways. Because PARP activation consumes NAD⁺ under oxidative stress, combining NR with an antioxidant such as EGT may spare newly synthesized NAD⁺.

3 | Mechanistic Synergy: EGT Spares NAD⁺ and Up-Regulates SIRT1/PGC-1α

In middle-aged Wistar rats, oral EGT (25 mg kg⁻¹ day⁻¹) increased skeletal muscle NAD⁺ by 28 % and elevated SIRT1, PGC-1α protein, and mitochondrial DNA copy number (Kawamura 2022). EGT-derived persulfidation of GAPDH augments its NAD⁺-regenerating step in glycolysis, providing an additional recycling route beyond NR's precursor pathway.

4 | Safety Lens: FDA GRAS Notice 001191 and Human PK at 10 mg day⁻¹

The U.S. FDA issued a "No-Questions" response to GRN 001191 (Dr.Ergo® L-ergothioneine) in 2025, supporting use up to 30 mg day⁻¹ in dietary supplements. A crossover human PK study showed plasma Tmax ≈ 1.5 h and no adverse events at 10-30 mg doses FDA GRN 001191 ↗.

A separate RCT (n = 44; Mayengbam 2023) confirmed that daily 10 mg EGT for 16 weeks raised plasma EGT six‑fold with no clinically significant lab changes Mayengbam 2023 ↗.

5 | Early Translational Signal: AbinoNutra® Liposomal NR + EGT Pilot

AbinoPharm's exploratory, open‑label pilot (n = 30; adults 35-60 y) used a delayed‑release liposomal capsule delivering NR 500 mg + EGT 10 mg + quercetin/resveratrol. After eight weeks: urinary 8-OHdG ↓34 %, fatigue (POMS-F) ↓22 %, no serious AEs; aligns with rodent EGT data. (Li 2025)）

6 | Looking Ahead

2025-26 RCTs will assess NR + EGT's effects on telomeres and DNA damage, potentially reshaping healthy-aging care.

SOURCE: AbinoPharm Inc